Glaxosmithkline Pharmaceuticals Ltd.
NSE: GLAXO · Pharmaceuticals
Snapshot
Unlock Glaxosmithkline Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
GlaxoSmithKline Pharmaceuticals Limited is a prominent Indian healthcare company engaged in the research, development, manufacturing, and commercialisation of pharmaceutical medicines and vaccines. Its diverse portfolio covers therapeutic areas including anti-infectives, respiratory, dermatology, gastrointestinal, and rare diseases.
Business Model
The company generates revenue through the sale of prescription and non-prescription pharmaceutical products and vaccines across domestic and international markets. It leverages a strong brand portfolio, including well-recognised names such as Augmentin, Calpol, and various vaccine lines, to maintain market presence.
- Incorporation Year:1924
Growth Outlook
Growth is expected to be driven by the company's focus on its core therapeutic segments and the expansion of its vaccine portfolio. Continued investment in research and development remains central to sustaining its competitive position in the Indian pharmaceutical landscape.
Key Risks
- Regulatory and Pricing Pressure. The company faces significant risks from government-mandated price controls on essential medicines in India, which can impact profit margins.
- Supply Chain and Manufacturing. Disruptions in the global supply chain for active pharmaceutical ingredients could adversely affect production schedules and product availability.
- Intense Market Competition. The pharmaceutical sector in India is highly competitive, with numerous domestic and multinational players vying for market share in key therapeutic categories.
- Intellectual Property Risks. The company's growth relies on the protection of its intellectual property and the successful navigation of patent litigation environments.
Start your research today
Unlock AI insights, financials, peers and live data on Glaxosmithkline Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,955 Cr
TTM · consolidated
NET PROFIT
₹1,068 Cr
TTM · consolidated
EPS
₹62.01
TTM · consolidated
RETURN ON EQUITY
50.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
61.2%
TTM · consolidated
P/E
47.7x
Q1 FY27 · consolidated
EV/EBITDA
32.7x
Q1 FY27 · consolidated
EBITDA MARGIN
37.9%
TTM · consolidated
NET PROFIT MARGIN
25.3%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Glaxosmithkline Pharmaceuticals Ltd.GLAXO | ₹50,112 Cr | 47.70 | 32.70 | 5.8% | 37.9% | 50.6% | 61.2% | +3.7% |
Alkem Laboratories Ltd.ALKEM | ₹62,054 Cr | 28.76 | 17.47 | 13.4% | 24.1% | 17.1% | 20.5% | -2.1% |
Abbott India Ltd.ABBOTINDIA | ₹55,386 Cr | 35.69 | 25.20 | 8.1% | 31.5% | 35.5% | 45.4% | -19.0% |
Ipca Laboratories Ltd.IPCALAB | ₹49,860 Cr | 38.07 | 20.90 | 10.6% | 23.7% | 18.3% | 19.4% | +46.8% |
Gland Pharma Ltd.GLAND | ₹48,373 Cr | 42.80 | 21.85 | 17.6% | 30.8% | 11.6% | 15.7% | +55.5% |
Ajanta Pharmaceuticals Ltd.AJANTPHARM | ₹43,288 Cr | 38.14 | 25.77 | 20.2% | 29.1% | 27.3% | 34.4% | +33.2% |
As of Q1 FY27
Financials
Glaxosmithkline Pharmaceuticals Ltd.
NSE: GLAXO · Pharmaceuticals
Snapshot
Unlock Glaxosmithkline Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
GlaxoSmithKline Pharmaceuticals Limited is a prominent Indian healthcare company engaged in the research, development, manufacturing, and commercialisation of pharmaceutical medicines and vaccines. Its diverse portfolio covers therapeutic areas including anti-infectives, respiratory, dermatology, gastrointestinal, and rare diseases.
Business Model
The company generates revenue through the sale of prescription and non-prescription pharmaceutical products and vaccines across domestic and international markets. It leverages a strong brand portfolio, including well-recognised names such as Augmentin, Calpol, and various vaccine lines, to maintain market presence.
- Incorporation Year:1924
Growth Outlook
Growth is expected to be driven by the company's focus on its core therapeutic segments and the expansion of its vaccine portfolio. Continued investment in research and development remains central to sustaining its competitive position in the Indian pharmaceutical landscape.
Key Risks
- Regulatory and Pricing Pressure. The company faces significant risks from government-mandated price controls on essential medicines in India, which can impact profit margins.
- Supply Chain and Manufacturing. Disruptions in the global supply chain for active pharmaceutical ingredients could adversely affect production schedules and product availability.
- Intense Market Competition. The pharmaceutical sector in India is highly competitive, with numerous domestic and multinational players vying for market share in key therapeutic categories.
- Intellectual Property Risks. The company's growth relies on the protection of its intellectual property and the successful navigation of patent litigation environments.
Start your research today
Unlock AI insights, financials, peers and live data on Glaxosmithkline Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,955 Cr
TTM · consolidated
NET PROFIT
₹1,068 Cr
TTM · consolidated
EPS
₹62.01
TTM · consolidated
RETURN ON EQUITY
50.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
61.2%
TTM · consolidated
P/E
47.7x
Q1 FY27 · consolidated
EV/EBITDA
32.7x
Q1 FY27 · consolidated
EBITDA MARGIN
37.9%
TTM · consolidated
NET PROFIT MARGIN
25.3%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27